# Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man

## Metadata
**Authors:** V Facchini, J A Timbrell
**Journal:** British Journal of Clinical Pharmacology
**Date:** 1981 Apr
**DOI:** [10.1111/j.1365-2125.1981.tb01131.x](https://doi.org/10.1111/j.1365-2125.1981.tb01131.x)
**PMID:** 7259927
**PMCID:** PMC1401654
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401654/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC1401654/pdf/brjclinpharm00210-0034.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC1401654/pdf/brjclinpharm00210-0034.pdf)

*Note: This is a scanned document with limited structured text. Full content available in PDF.*

## Abstract

1 The 0-24 h urine from hypertensive patients treated with hydralazine (100 mg twice daily) has been analysed by gas chromatography and high pressure liquid chromatography. 2 4-N-Acetylhydrazinophthalazine-1-one (NAcHPZ), s-triazolo [3, 4-a] phthalazine (TP), phthalazinone (PZ) and hydralazine (free, H; acid-labile hydrazones, HH) were detected and assayed. 3 The results indicate that slow acetylators excrete less NAcHPZ and TP than rapid acetylators but more PZ and HH. 4 Free hydralazine was present in low levels and was only detected in some urine samples. 5 The ratios of the metabolites NAcHPZ/HH; TP/HH; NAcHPZ/PZ and PZ/TP are different in the two acetylator phenotypes. 6 It is possible the ratio PZ/TP may be used for determination of acetylator phenotype. 7 It is concluded that hydralazine metabolism is dependent on the acetylator phenotype.

## Full Text (Scanned Pages)

### Page 1
![345](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78dc/1401654/e1784830188b/brjclinpharm00210-0034.png)

### Page 2
![346](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78dc/1401654/ca1874aaac6d/brjclinpharm00210-0035.png)

### Page 3
![347](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78dc/1401654/85049394f179/brjclinpharm00210-0036.png)

### Page 4
![348](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78dc/1401654/4c985607d139/brjclinpharm00210-0037.png)

### Page 5
![349](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78dc/1401654/ea8568548844/brjclinpharm00210-0038.png)

### Page 6
![350](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78dc/1401654/8fe6638bf7ea/brjclinpharm00210-0039.png)

### Page 7
![351](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78dc/1401654/c75c96b60372/brjclinpharm00210-0040.png)
